author-photo

Johnny B. Roy

University of Oklahoma

22

Papers

1153

Citations

Citation Trend

Filter By

Papers (22) Sort By

Journal Conference Others

Incidence and severity of sexual adverse experiences in finasteride and placebo-treated men with benign prostatic hyperplasia.

2003 Urology
Show All
- Source
- Cite
- Save
Citations (118)
Long-term (7 to 8-year) experience with finasteride in men with benign prostatic hyperplasia

2002 Urology
Show All
- Source
- Cite
- Save
Citations (63)
Serum prostate specific antigen is a strong predictor of future prostate growth in men with benign prostatic hyperplasia. PROSCAR long-term efficacy and safety study.

2000 The Journal of Urology
Show All
- Source
- Cite
- Save
Citations (128)
Efficacy of finasteride is maintained in patients with benign prostatic hyperplasia treated for 5 years

1999 Urology
Show All
- Source
- Cite
- Save
Citations (51)
Biologic Variability of Prostate-Specific Antigen and its Usefulness as a Marker for Prostate Cancer: Effects of Finasteride

1997 Urology
Show All
- Source
- Cite
- Save
Citations (52)
Biologic variability of prostate-specific antigen and its usefulness as a marker for prostate cancer: effects of finasteride. The Finasteride PSA Study Group.

1997 Urology
Show All
- Source
- Cite
- Save
Citations (41)
A deficit of chondroitin sulfate proteoglycans on the bladder uroepithelium in interstitial cystitis

1996 Urology
Show All
- Source
- Cite
- Save
Citations (117)
Proscar: five-year experience

1995 European Urology
Show All
- Source
- Cite
- Save
Citations (55)
Doxazosin for the treatment of benign prostatic hyperplasia in patients with mild to moderate essential hypertension: a double-blind, placebo-controlled, dose-response multicenter study.

1995 The Journal of Urology
Show All
- Source
- Cite
- Save
Citations (167)
Urinary Glycosaminoglycan Excretion as a Laboratory Marker in the Diagnosis of Interstitial Cystitis

1993 The Journal of Urology
Show All
- Source
- Cite
- Save
Citations (67)